Aura Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Aura Biosciences, Inc. (AURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 91.04% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-11
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 91.04%, a 0.26% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 102.43%, a 12.70% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 91.02%, a 2.48% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 90.80%, a 1.91% increase year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 91.65%, a 3.41% increase from fiscal 2024.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 88.63%, a 2.88% increase from fiscal 2023.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 86.15%, a 10.31% increase from fiscal 2022.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 78.10%, a 5.73% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 91.04% 10-Q · filed 2026-08-11 | 95.74% 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 102.43% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 91.65% 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 91.02% 10-Q · filed 2025-11-13 | 90.87% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 90.80% 10-Q · filed 2026-08-11 | 90.87% 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | 90.89% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 88.63% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 88.82% 10-Q · filed 2025-11-13 | 88.61% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 89.10% 10-Q · filed 2025-08-13 | 88.59% 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | 88.50% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 86.15% 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 87.35% 10-Q · filed 2024-11-12 | 85.38% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 85.43% 10-Q · filed 2024-08-08 | 84.97% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 84.83% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 78.10% 10-K · filed 2024-03-27 | |||
| 2022-09-30 | 79.01% 10-Q · filed 2023-11-09 | 76.76% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 76.85% 10-Q · filed 2023-08-09 | 75.44% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 73.02% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 73.87% 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 73.36% 10-Q · filed 2022-11-10 | 74.21% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 74.43% 10-Q · filed 2022-08-11 | 74.37% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 73.16% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 74.04% 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 73.71% 10-Q · filed 2021-11-24 | 74.16% 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |